Form 4 Filing for BridgeBio Pharma, Inc. (BBIO)

This filing details transactions by Frank McCormick, a director at BridgeBio Pharma, Inc. On June 22, 2026, McCormick acquired 3,990 shares of Common Stock via a restricted stock unit (RSU) grant under the company's incentive plan. These RSUs vest on June 22, 2027, contingent on continued service. Additionally, McCormick was granted a stock option to buy 5,277 shares of Common Stock, exercisable at $68.92 per share, with vesting also set for June 22, 2027. The filing also clarifies a previously reported transfer of 352,290 shares, stating that no change in beneficial ownership occurred at that time. McCormick's holdings include 756,665 shares held indirectly through a trust and 10,579 shares held directly following the RSU transaction. The option shares vest under similar conditions as the RSUs.